FIELD: medicine; oncology.
SUBSTANCE: invention can be used to predict the development of distant metastases in the next four weeks in patients with unresectable triple-negative breast cancer. In the tumor microenvironment, lymphocytes expressing FOXP3 and CD8 markers are determined. In the culture of lymphocytes the level of spontaneous production of IL-10 and IL-8 is determined in pg/ml. The absolute concentration of cells with markers LIN-HLADR-CD33+CD66b-CD14+CD15- is determined in the blood. Based on the obtained values, discriminant functions are calculated and the development of distant metastases is predicted in the next four weeks.
EFFECT: method makes it possible to predict the development of distant metastases in patients with triple-negative breast cancer by assessing immunological parameters in the blood and tumor microenvironment by flow cytometry.
1 cl, 9 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTING THE DURATION OF A RELAPSE-FREE PERIOD IN PATIENTS WITH RESECTABLE THRICE-NEGATIVE BREAST CANCER | 2021 |
|
RU2780922C1 |
| METHOD FOR DETERMINING THERAPEUTIC APPROACH IN PATIENTS WITH METASTATIC FORMS AND RECURRENT TRIPLE-NEGATIVE BREAST CANCER | 2023 |
|
RU2818730C1 |
| METHOD FOR PREDICTION OF LIFE EXPECTANCY IN PATIENTS WITH METASTATIC TUMORS | 2023 |
|
RU2821659C1 |
| METHOD FOR ASSESSING THE SENSITIVITY OF A TUMOR TO IMMUNO-ONCOLOGICAL DRUGS | 2021 |
|
RU2771760C1 |
| METHOD OF ASSESSING IMMEDIATE RESULTS OF TREATMENT OF PATIENTS WITH DISSEMINATED FORMS OF MALIGNANT TUMORS | 2023 |
|
RU2806483C1 |
| METHOD FOR TREATING THRICE-NEGATIVE BREAST CANCER | 2017 |
|
RU2757905C2 |
| METHOD FOR LIFESPAN EVALUATION IN PATIENTS WITH LOCALLY ADVANCED AND DISSEMINATED RENAL CELL CARCINOMA | 2009 |
|
RU2405150C1 |
| METHOD FOR MULTIVARIATE PROGNOSIS OF BREAST CANCER | 2021 |
|
RU2763839C1 |
| METHOD FOR PREDICTION OF ESOPHAGEAL CANCER PROGRESSION | 2016 |
|
RU2640954C1 |
| METHOD FOR ONCOLOGICAL DISEASES COURSE PREDICTION | 2016 |
|
RU2622756C1 |
